Frank Bucci, MD
Ophthalmology · Wilkes Barre, PANPI 1366425704
Payments from drug & device makers
Across 335 payments — averaging $2666.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$377K
- Ocular Therapeutix, Inc.$241K
- Rxsight Inc$121K
- AbbVie$81K
- Novartis$51K
- Tearlab Corp$5K
- plus $18K from 22 others
Across 3 payments — averaging $47,333 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Johnson & Johnson Surgical Vision, Inc.$142K
What the payments were for
- Consulting fees$224,25991%
- Speaking & faculty fees$2,1261%
- Travel & lodging$2,0901%
- Food & beverage$17,1317%
- Gifts$2020%
- Entertainment$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 101 | $376,995 |
| Ocular Therapeutix, Inc. | 25 | $240,899 |
| Rxsight Inc | 11 | $120,673 |
| AbbVie(2 entities) | 39 | $81,158 |
| Novartis | 8 | $51,165 |
| Tearlab Corp | 9 | $4,818 |
| Lensar, Inc. | 16 | $4,634 |
| Bausch & Lomb Americas Inc. | 15 | $2,518 |
| Glaukos Corporation | 15 | $2,456 |
| Bausch Health US, LLC | 3 | $2,236 |
| NEW World Medical,inc. | 9 | $1,515 |
| Carl Zeiss Meditec, Inc. | 6 | $765 |
| Alcon | 18 | $640 |
| Tarsus Pharmaceuticals, Inc. | 9 | $557 |
| Sun Pharmaceutical Industries Inc. | 12 | $545 |
| Rayner Intraocular Lenses Limited | 7 | $294 |
| Kala Pharmaceuticals, Inc. | 5 | $264 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $223 |
| Shire North American Group Inc | 3 | $220 |
| Ivantis, Inc | 1 | $129 |
| Johnson & Johnson Vision Care, Inc. | 1 | $121 |
| Staar Surgical Company | 3 | $120 |
| Beaver-visitec International, Inc. | 1 | $119 |
| Biotissue Holdings Inc. | 5 | $90 |
| Sight Sciences, Inc. | 3 | $84 |
| Omeros Corporation | 2 | $62 |
| Harrow Eye, LLC | 2 | $58 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT CONTACT LENS$120,224
- RXSIGHT INJECTOR CARTRIDGE$120,224
- RXSIGHT INJECTOR HANDPIECE$120,224
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$120,224
- LIGHT ADJUSTABLE LENS (LAL)$120,224
- DEXTENZA$63,583
- Tecnis Multifocal Family of 1-piece IOLS$15,898
- Tecnis Toric 1-piece IOL$14,173
- Tecnis 1-piece IOL$7,346
- Tecnis 3-piece IOL$7,200
- Tecnis Symphony IOL$6,600
- Tecnis Symphony Toric IOL$6,600
- LENSAR LASER SYSTEM$4,634
- TearLab Osmolarity System$4,550
- Compact Intuitiv$4,219
- IFS ADVANCED FEMTOSEC LASER$4,219
- Tecnis IOL$3,213
- COMPACT INTUITIV Phacofragmentation System$2,500
- iStent inject Trabecular Micro-Bypass Stent System$1,500
- Catalys Laser System$1,250
How this compares
$893,378 in reported general payments places this provider in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 762 | $23,139 |
| RestasisCyclosporine | 18 | $17,585 |
| Cyclosporine | 15 | $8,464 |
| Ofloxacin | 734 | $8,036 |
| Ketorolac Tromethamine | 640 | $7,964 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 24 | $4,825 |
| Travoprost | 13 | $2,821 |
| Alphagan PBrimonidine Tartrate | 13 | $2,235 |
| Latanoprost | 97 | $1,033 |
| Fluorometholone | 17 | $1,006 |
| Timolol Maleate | 42 | $784 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Alphagan P | $81,158 | $19,82131 claims |
| AlconSimbrinza | $640 | $4,82524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Other ophthalmology in Wilkes Barre
- David AlmeidaErie$6.3M
- William ChristieCranberry Township$5.2M
- Carl RegilloPlymouth Meeting$3.2M
- Erik KrugerKingston$3M
- Sunir GargPlymouth Meeting$2M
- Allen ChiangPlymouth Meeting$1.6M
- Julia HallerPhiladelphia$1.5M
- Mitchell FinemanPlymouth Meeting$1.3M
- Allen HoPlymouth Meeting$1.3M
- Brandon AyresBala Cynwyd$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.